The prevention and treatment of venous thromboembolism (VTE) poses distinct gender-specific challenges. Women of childbearing age are at an increased risk of VTE secondary to the transient risk factors of combined hormonal contraception (CHC) and pregnancy. Cancers specific to women are associated with a significant burden of VTE; whilst the incidence of VTE in localised breast cancer is 5 per 1000 personyears, more cases are seen due to the prevalence of breast cancer. Treatment of VTE in women can be complicated by abnormal uterine bleeding, now increasingly reported with direct oral anticoagulants (DOACs) as well as vitamin K antagonists. Divergence between international guidelines regarding the use of CHC following an oestrogen-associated VTE and appropriate withdrawal of such contraception requires clarification for clinicians. Additionally, there is uncertainty as to whether to consider such events provoked or unprovoked and, consequently, the optimal duration of treatment in these women remains unclear. During pregnancy and the puerperium, the traditional anticoagulants remain the agents of choice with no further advances in DOAC safety data, and similarly in lactation. Further studies evaluating the safety and optimal treatment strategies in these women are awaited.
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Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects 1-2 in 1000 patient years and is the third most common cause of cardiovascular death (Anderson et al, 1991; Oger, 2000) . Women face a greater risk of thrombosis throughout their reproductive years due to transient factors, such as hormonal therapy and pregnancy. Women diagnosed with VTE face additional challenges with anticoagulation therapy, experiencing more bleeding complications. Additionally, there are limited anticoagulant options suitable for use in pregnancy or breastfeeding. Whilst the direct oral anticoagulants (DOACs) have transformed global anticoagulation practice, they have not resolved the problem of heavy menstrual bleeding (HMB) for anticoagulated women and there remains a lack of safety data for use in pregnancy or breastfeeding. This review article will describe the VTE risk profile in women and the complexities of treatment with anticoagulation therapy.
VTE risk in women
Men and women have an overall similar lifetime risk of developing a first episode of VTE (Douketis et al, 2011) . A retrospective US claims database review suggested women had a higher prevalence of VTE (Burwen et al, 2017) , but this has not been demonstrated elsewhere. Of note, the incidence rate of VTE is reported to be higher in women of child-bearing age (probably reflecting the use of hormonal contraceptives and pregnancy), with men having higher incidence rate once over 45 years of age (Silverstein et al, 1998) . This is supported by a five-fold increase in VTE risk in women with reproductive risk factors (Roach et al, 2014) . Gender also appears to modulate presentation of VTE, with data from three large registries demonstrating more frequent PE presentation in women compared to men (Scheres et al, 2017) , with up to 10% more PE in women than men. This sex difference was more marked in unprovoked VTE and was independent of age.
Risk of VTE with hormonal contraception
The increased risk of VTE associated with hormonal contraception was recognised in the 1960s when the contraceptive pill was first introduced (Jordan & Anand, 1961) . Women and prescribers select combined hormonal contraceptives (CHC) for contraceptive purposes but also as specific therapy for acne, polycystic ovarian syndrome and menorrhagia and/ or dysmenorrhea. The risk of VTE in women of childbearing age in the absence of hormonal contraception is 0Á19-0Á36 per 1000 persons year (Samuelsson & H€ agg, 2004; Lidegaard et al, 2011) . A Cochrane review established that the use of oral combined hormone preparations increased VTE risk by fourfold (relative risk (RR) 3Á5, 95% CI 2Á9-4Á3), based on data from 15 studies (De Bastos et al, 2014) . Of note, the absolute risk remains low. This Cochrane review highlighted the increased risk of VTE with all combined oral contraceptives, and that the risk of VTE increases with both dose of oestrogen and type of progestin. They reported the lowest VTE risk with 30-35 lg of ethinyloestradiol and levonorgestrel (LNG), with a 50-80% increase in risk with gestodene, desogestrel, cyproterone acetate and drospirenone (De Bastos et al, 2014) . Increasing dose of progestin additionally increased VTE risk. A subsequent large observational cohort study of >4 million women on CHC in France found LNG combined with 20 lg of oestrogen was associated with the lowest risk of PE, compared with higher oestrogen doses and alternate progestin preparations (Weill et al, 2016) .
Importantly, the increased VTE risk is not limited to oral preparations; a retrospective study of four national Danish registries covering 1Á9 million women identified use of combined contraceptive transdermal patches and combined vaginal rings as significantly associated with VTE with a RR of 7Á9 (95% CI 3Á5-17Á7) and 6Á5 (95% CI 4Á7-8Á9), respectively, compared to non-users of hormonal contraception (Lidegaard et al, 2012) . The VTE risk associated with these preparations was also significantly higher than that in users of oral combined preparations (transdermal patch RR 2Á3, 95% CI 1Á0-5Á2 and vaginal ring RR 1Á9, 95% CI 1Á3-2Á7).
Progestin-only preparations are generally considered low risk for VTE, despite evidence that type and dose of progestin within combined oral preparations influences VTE risk. A meta-analysis of eight studies of progestin-only contraception did not identify a relationship between VTE and oral progestin-only contraception (RR 0Á90, 95% CI 0Á57-1Á45), nor progestin intra-uterine devices (IUDs), RR 0Á61, 95% CI 0Á24-1Á53) but reported a two-fold increase associated with injectable progestin contraception (RR 2Á67, 95% CI 1Á29-5Á53) compared to non-users of hormonal contraception. Of note, only two studies were included in the analysis on non-oral progestin preparations (Mantha et al, 2012) and these findings require further confirmation. The Danish registry study supports these findings, with no increased VTE risk seen with progestin IUD (RR 0Á6, 0Á4-0Á8) but suggestion of increased VTE risk with subcutaneous progestin implants (RR 1Á4, 0Á6-3Á4) (Lidegaard et al, 2012) .
VTE risk with hormone replacement therapy
The risk of VTE increases 2-to 4-fold in postmenopausal women using hormone replacement therapy (HRT) (Høi-braaten et al, 2000; Roach et al, 2013) . Patients using transdermal preparations of HRT have a lower risk of VTE compared with those on oral preparations. A meta-analysis of eight observational and nine randomised controlled trials reported oral oestrogen was associated with a significantly increased odds ratio (OR) for first VTE of 2Á5 (95% CI 1Á9-3Á4) compared to non-users with a lesser risk seen with transdermal preparations (OR 1Á2, 95% CI 0Á9-1Á7) (Canonico et al, 2008) . The risk of VTE was highest in the first year of therapy, and was greater in those with higher body mass index (BMI) and underlying thrombophilia. Data from postmenopausal women participating in the Million Women Study (>1 million women in the UK), confirmed the highest risk of VTE was associated with combined (oestrogen and progestin) preparations (OR 2Á07, 95% CI 1Á86-2Á31), with oral oestrogen associated with an OR of 1Á42 (95% CI 1Á21-4Á66) and no increased VTE risk with transdermal oestrogen (OR 0Á82, 95% CI 0Á64-1Á06) (Sweetland et al, 2012) . Data from the MEGA (Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis) study (case control study including 2550 women >50 years) further support these findings, with oral HRT conferring a four-fold increase in risk (OR 4Á0, 95% CI 1Á8-8Á2) and no increase in VTE risk with transdermal oestradiol (OR 1Á1, 95% CI 0Á6-1Á8) (Roach et al, 2013) . A later meta-analysis of 15 observational studies confirmed higher VTE risk with oral HRT compared to transdermal preparations (RR 1Á63, 95% CI 1Á4-1Á9) (Mohammed et al, 2015) .
VTE risk in transgender women
A transgender individual has a gender identity that does not align with their assigned sex at birth. Hormonal therapy forms the backbone of medical therapy for those undergoing gender transition. Of relevance to this review, is the male to female transgender women. Hormonal therapy is prescribed to develop secondary sexual characteristics followed by gender-affirming surgery, although not all patients go on to have surgery. Hormonal treatment continues even after surgery to prevent osteoporosis and vasomotor symptoms.
There is a lack of prospective studies regarding the risk of VTE in transgender patients. Small retrospective cohort studies report the risk of VTE to be as high as 20-to 45-fold greater than would be expected for individuals of the same age, with a significant reduction in risk seen in more recent years, reflecting a change in clinical practice to use oestradiol rather than ethinyloestradiol (Asschemann et al, 2014) . A case control study (transwomen, n = 214) reported a 5% incidence of VTE with five events occurring on HRT and a further three at the time of gender-affirming surgery (Wierckx et al, 2013) . A recent retrospective chart review from a single centre prescribing oral oestradiol to transgender women (n = 676) reported a low incidence of VTE of 7Á8 per 10 000 patient-years (Arnold et al, 2016) . In contrast, a large cohort study of transgender members of integrated health care systems in the US found a greater incidence of VTE in transwomen individuals (n = 2842) with 2-and 8-year risk differences of 4Á1 (95% CI, 1Á6-6Á7) and 16Á7 (CI, 6Á4-27Á5) per 1000 persons compared to cisgender men and 3Á4 (CI, 1Á1-5Á6) and 13Á7 (CI, 4Á1-22Á7) compared to cisgender women (Getahun et al, 2018) . There is a need for further prospective research to define the risk within this group; in the UK, the majority of hormonal therapy is unlicensed and patients are typically managed under a joint care model. Self-prescribing of hormones is reported to be as high as one in four in transwomen. This hampers both prospective research and, potentially, user awareness of side effects (Mepham et al, 2014) .
Cancer in women and VTE risk
Thrombosis is a common cause of death in cancer patients, second only to cancer. The overall incidence of VTE in cancer patients was reported as 1% in a meta-analysis by Horsted et al (2012) , with wide variation by cancer subtype and over time. We further discuss cancers specific to women, including breast (also diagnosed in men but at significantly lower frequency) and gynaecological malignancies. In the UK, there were 55 122 new diagnoses of breast cancer in 2015, with a further 20 951 women diagnosed with gynaecological malignancy (Cancer Research UK, 2015) . Female sex has been reported to be associated with higher rates of VTE in breast and haematological malignancies, with a lower frequency of VTE in lung cancer (Farge et al, 2017) .
The meta-analysis by Horsted et al (2012) further examined VTE incidence in eight cancer subtypes, including breast cancer. Compared with bone, brain, colorectal, haematological, lung, pancreatic and prostate cancer, breast cancer was associated with the lowest VTE risk in 'average risk' groups (5 per 1000 person-years) and increasing to 55 per 1000 person-years in 'high-risk' populations (defined as populations with all or majority of participants having metastatic disease or undergoing treatment for cancer including surgery, radiotherapy or chemotherapy). The cumulative incidence of VTE by cancer subtype has been estimated using linked Dutch cancer registry data with anticoagulation clinics. In the first 6 months the rate per 1000 patients was reported as 8Á0 (95% CI, 6Á4-9Á8) for breast cancer, 16Á2 (95% CI, 9Á6-27Á1) for endometrial cancer and 32Á6 (95% CI, 24Á5-43Á1) for ovarian cancer compared to 12Á3 (95% CI, 11Á5-13Á0) for all cancer subtypes (Blom et al, 2006) . A similar data linkage study in California reported 1-and 2-year-cumulative incidences by both cancer subtype and disease stage, with a higher incidence in the first year (Chew et al, 2006) . For localised breast cancer, the 2 year cumulative incidence was 0Á8%, increasing to 2Á6% with metastatic disease compared with 1Á2% and 4Á8% for localised and metastatic uterine cancer respectively and 0Á8% and 4Á4% for local and metastatic ovarian cancer respectively (Chew et al, 2006) . A large cohort study in England, using combined Clinical Research Practice Database, Hospital Episode Statistics, Cancer Registry and Office of National Statistics data, described the risk of VTE associated with cancer subtypes (n = 83 203) compared to healthy, age and gender matched controls without cancer (n = 577 207). Breast cancer was associated with a RR of 3Á5 (95% CI 3Á2-3Á9), cervical cancer RR 9Á8 (95% CI 7Á2-14), ovarian cancer RR 13 (95% CI 11-15) and uterine cancer RR 4Á0 (95% CI 4Á3-5Á9) (Walker et al, 2013) .
Cancer in women and treatment-specific VTE risks Surgery. Major cancer surgery is a recognised risk factor for VTE with post-operative VTE rates of 1Á5-3Á1% (Agnelli et al, 2006; Osborne et al, 2008; Farge et al, 2017) . A study investigating VTE rates following eight types of major cancer surgery reported female gender to be associated with an increased risk of VTE (OR 1Á25, P < 0Á001) (Trinh et al, 2014) . However, the study included gender-specific uterine cancer (with known higher risk of VTE) and prostate cancer (with a relatively lower risk of VTE), which may have contributed to this reported difference.
The 30-day incidence of VTE following mastectomy for breast cancer was reported as 0Á23% in a single cohort of 49 028 women (Tran et al, 2013) . Rates of VTE at 30 days following surgery for gynaecological malignancy have been reported from the American College of Surgeons National Surgical Quality Improvement Program (ASC-NSQIP) and are markedly higher at 3% post-ovarian cancer surgery, 1Á4% post-uterine cancer surgery, 1Á5% post-cervical cancer surgery and 1Á3% post-vulval cancer surgery (Graul et al, 2017) . A retrospective cohort study of 569 patients following debulking surgery for ovarian cancer estimated a 6Á5% (95% CI 4Á4-8Á6%) incidence of VTE at 30 days (Mokri et al, 2013) .
Medical therapy. Chemotherapy is reported as increasing the risk of VTE by 2-to 6-fold (Blom et al, 2006; Rogers et al, 2012) . Aggressive regimens, such as platinum-based therapy, are recognised as being associated with increased VTE risk. In a pooled analysis of three randomised controlled trials comprising 2743 patients with advanced ovarian cancer treated with platinum paclitaxel regimes, the rate of VTE was reported as 2Á8% during 6-11 cycles of adjuvant chemotherapy (Fotopoulou et al, 2008) . Of note, half of all episodes occurred within 2 months of debulking surgery. A further review of VTE in patients with recurrent ovarian cancer, reported a 7% incidence of VTE during chemotherapy, with the majority of events occurring within 2 months of initiation (Fotopoulou et al, 2009 ).
Hormone therapy. Tamoxifen is a selective oestrogen receptor modulator with an established role in the prevention of breast cancer recurrence among women with oestrogen receptor-positivity (accounting for~70% of breast cancer) (Farge et al, 2017) . It is reported to increase the risk of VTE by 2-to 3-fold in healthy women when used as primary prevention for those at high risk of breast cancer (https://www. medicines.org.uk/emc/product/4392/smpc; Cuzick et al, 2003; Decensi et al, 2005) .
Danish registry data from 16 289 women described the incidence and timing of VTE in women prescribed tamoxifen versus placebo after breast cancer surgery and reported a 1Á2% 5-year incidence in women receiving tamoxifen associated with a RR 2Á4 (95% CI 1Á6-3Á4) compared to women not on tamoxifen. This risk was highest in the first 2 years and in women >50 years (Hernandez et al, 2009) . Aromatase inhibitors (letrozole, anastrozole and exemestane) are associated with reduced breast cancer recurrence rates and improved disease-free survival (compared with tamoxifen) in post-menopausal women with breast cancer and a meta-analysis of this patient group treated with aromatase inhibitors reported a significant reduction in VTE (OR 0Á55, 95% CI 0Á46-0Á64) compared to tamoxifen use (Amir et al, 2011) .
Primary prevention of VTE in women
The majority of VTE risk factors are not gender-specific; surgery and hospitalisation account for 46% of VTE (Heit et al, 2002) . All patients should have a VTE risk assessment upon admission to hospital with appropriate thromboprophylaxis offered irrespective of gender (Geerts et al, 2008 ; National Institute for Health and Care Excellence [NICE], 2018a). In the pre-operative setting, risk assessment should include consideration of withdrawal of oestrogen-containing CHC or HRT 4 weeks prior to elective surgery to minimise VTE risk in such women post-operatively. Two large multi-centre studies have demonstrated that extended thromboprophylaxis following abdominal or pelvic cancer surgery reduces the risk of VTE by up to 60% (Bergqvist et al, 2002; Kakkar et al, 2010) . NICE, American College of Chest Physicians (ACCP) and American Society of Clinical Oncology (ASCO) recommend the use of extended thromboprophylaxis for 28 days in this patient group, and this is applicable to women undergoing major pelvic surgery for gynaecological malignancy (Gould et al, 2012; Lyman et al, 2015; NICE, 2018a) .
Similarly, women should be clinically assessed for VTE risk at initiation of contraception and/or HRT. The UK medical eligibility criteria classify history of prior VTE as an unacceptable risk with ongoing prescription of CHC irrespective of use of anticoagulation (Faculty of Sexual and Reproductive Healthcare [FSRH], 2016) . Additionally, it recommends that expert advice should be sought prior to commencing CHC for women with a family history of VTE in a first-degree family member (at <45 years of age). However, for some women for whom there is no suitable alternative to CHC, e.g. those with polycystic ovarian syndrome, it may be appropriate to prescribe these agents following detailed counselling of the risks and modification of reversible risk factors (e.g. smoking and obesity). This counselling should include explanation of the low absolute risk of thrombosis and the likely impact of additional risk factors on VTE risk in association with CHC use. Extended anticoagulation may be considered for women with a personal history of VTE, particularly if the prior event was unprovoked, associated with CHC or pregnancy (see below). The FSRH considers progestin-only preparations for contraception as low risk for VTE (FSRH, 2017) . NICE guidelines for diagnosis and management of menopause recommend counselling women regarding the increased risk of VTE associated with HRT. Women at risk for VTE should be preferentially initiated on transdermal preparations. Consideration of a haematological opinion is suggested for those with a strong family history of VTE or a hereditary thrombophilia before initiating HRT (NICE, 2015) .
The World Professional Association for Transgender Health and the Endocrine Society provide guidance on hormonal therapy in transgender patients and recommend against the use of ethinyloestradiol due to its apparent higher VTE risk (Toorians et al, 2003) . Transdermal preparations are recommended for those with risk factors for VTE (Coleman et al, 2012) . Furthermore, the Endocrine Society recommends supervised therapy and in-depth counselling prior to initiation regarding the risk and benefits of hormonal therapy. Additionally, reversible risk factors, such as smoking, should be addressed in transgender females to reduce the risk of VTE and cardiovascular complications (Hembree et al, 2017) .
Women requiring adjuvant tamoxifen therapy should also have their VTE risk evaluated irrespective of the presence of ongoing active malignancy; the absolute risk of VTE is insufficient to warrant provision of thromboprophylaxis to all users but may be considered for those with prior VTE (see below).
Venous thromboembolism risk assessment is an integral component of routine antenatal care in the United Kingdom and is outlined in detail in the current Royal College of Obstetrics and Gynaecology (RCOG) Green-top Guideline 37a (RCOG, 2015) and is not further reviewed here.
Women's health and treatment of VTE
In this section, we review the choice of treatment in pregnancy and breastfeeding, management of hormone therapy, the role of female gender and duration of anticoagulation, and adverse effects of anticoagulation unique to women. Following a diagnosis of VTE, the minimum duration of anticoagulation is now accepted as 3 months, with extended treatment for at least 6 months for cancer-associated thrombosis NICE, 2012) .
Choice of VTE treatment in pregnancy/breastfeeding
When pregnant women present with suspected VTE, there are a number of unique challenges that need to be overcome; the diagnostic algorithm which is followed, the treatment prescribed, the management of anticoagulation at the time of delivery and postpartum management. Detailed discussions of these challenges are beyond the scope of this review and readers are referred to excellent reviews (Arya, 2011; Middeldorp, 2011 ) and the current RCOG guidelines for the treatment of antenatal VTE (RCOG, 2015) .
At present low molecular weight heparin (LMWH) remains the treatment of choice for the management of antenatal VTE, based on a systematic review of 64 reports in 2777 pregnancies demonstrating a low risk of VTE recurrence of 1Á15% (Greer & Nelson-Piercy, 2005) . Despite this, the parenteral nature of LMWH remains a significant limitation, although work from our own group suggests that women are largely adherent to treatment during the antenatal period despite the inconvenience of parenteral therapy (Patel et al, 2012) . Routine monitoring of anti-Xa activity is not required in pregnancy except in those at extremes of body weight (less than 50 kg or greater than 90 kg) or who have other complicating factors, such as renal disease or recurrent VTE (RCOG 2015) . Currently all DOACs are contra-indicated during the antenatal period. Reproductive animal studies have shown that dabigatran, edoxaban and rivaroxaban produce toxicity in a rat model with evidence of transplacental passage of dabigatran. Animal studies with apixaban have shown no direct or indirect harmful effects (Bapat et al, 2014 ; https://www.medicines.org.uk/emc/medic ine/27220; https://www.medicines.org.uk/emc/medicine/25586; https://www.medicines.org.uk/emc/medicine/30506; https:// www.medicines.org.uk/emc/medicine/24839). As DOAC use is increasing worldwide, it's unsurprising that some women are inadvertently exposed to these agents, often whilst being managed for VTE outside of the gravid state. A retrospective report of 233 cases of pregnancy exposure to DOACs with 137 known outcomes reported seven abnormalities (5Á1%) of which three (2Á2%) were interpreted as embryopathy: live birth with facial dysmorphism; miscarriage in week 10 with limb abnormality; elective pregnancy termination due to a fetal cardiac defect in a woman who had to terminate a previous pregnancy due to Fallot tetralogy (Beyer-Westendorf et al, 2016a). It's difficult to draw any robust conclusions from this early data and a multi-centre, international registry is underway to collect both retrospective and prospective data on women exposed to DOAC during pregnancy and will hopefully provide further insights regarding the safety of these agents in this setting (International Society on Thrombosis and Haemostasis [ISTH], 2015) . The ISTH recommends that women of child-bearing potential are thoroughly counselled on the risks of becoming pregnant whilst on a DOAC and that if pregnancy is desired to make a preconceptual switch to an alternative safe agent . Termination is not recommended by the ISTH following inadvertent DOAC exposure, but they suggest that patients should have nondirective counselling. Where pregnancy is continued and DOAC exposure confirmed then early obstetric review and pregnancy surveillance is recommended.
Safety is not the only factor to consider. Due to the physiological changes of pregnancy (Anderson, 2005) , the gravid state is well recognised in altering the pharmacokinetics of medicines. Indeed, the dosing of LMWH requires special consideration with respect to this (RCOG, 2015) . Therefore, if the safety of an individual DOAC is established during pregnancy, the question of whether the DOAC dose needs altering will need to be considered, particularly because each DOAC has unique pharmacokinetic properties (Steffel et al, 2018) .
Breastfeeding
Vitamin K antagonists (VKA), LMWH and unfractionated heparin (UFH) are considered safe to use, whilst women are breastfeeding (RCOG, 2015) . DOACs would, once again, provide an attractive alternative to traditional anticoagulants during the puerperium. Animal studies from all the direct factor Xa inhibitors suggest that they will transfer into breastmilk and, for rivaroxaban, a single case report has confirmed this to be the case in humans (Wiesen et al, 2016) . No animal data for dabigatran exists, however data from the Dalmation study [Eudra CT 2014-004249-29] has recently posted results from two subjects of their open-label phase II clinical trial of dabigatran in breastfeeding women, which suggest that dabigatran does transfer into breastmilk [available at https://www.clinicaltrialsregister.eu/ctr-search/trial/ 2014-004249-29/results]. If the results from these early case reports and the Dalmation study are replicated, then the question to consider will be whether the amount of DOAC transfer into breastmilk is clinically significant. Studies are underway by the manufacturers of the different DOACs, evaluating their agents in the paediatric population, and the pharmacokinetic data from these will aid in determining the clinical relevance of any transfer into breastmilk. In the meantime, breastfeeding women should be managed with LMWH, VKA or UFH, as appropriate.
Management of hormonal therapy following VTE
There is controversy regarding the management of hormonal therapy in women diagnosed with VTE. Given this represents a potential provoking factor, hormone therapy should be withdrawn where possible. The World Health Organization (WHO) recommends cessation of CHC at VTE diagnosis whereas the ISTH Scientific and Standardization Committee recommends withdrawing hormone therapy prior to stopping the recommended course of anticoagulation WHO, 2015) . An international survey of thrombosis experts, abnormal uterine bleeding (AUB) experts and the ISTH community reported divergent results (Klok et al, 2017) . Arguments for maintaining women on CHC are avoiding unwanted pregnancy, particularly soon after the diagnosis of VTE, the need for contraception in women of child-bearing age treated with direct oral anticoagulants and that withdrawal of CHCs may exacerbate HMB during anticoagulation, particularly in women for whom CHCs were commenced to address HMB.
Women with VTE should be managed with an alternative contraception where possible; progestin-only preparations are considered low risk by the FSRH (FSRH 2017). The withdrawal of CHC in a planned way with an alternative contraception can avoid withdrawal bleeding and an unwanted pregnancy. For some women, there may not be a suitable alternative, for example, women with polycystic ovarian syndrome, and continued anticoagulation whilst on CHC should be advocated for the duration of CHC. This approach has been demonstrated to effectively reduce the risk of recurrent VTE (Martinelli et al, 2016) . Similarly, whilst there is no prospective evidence to support this approach in the transgender population, concomitant anticoagulation may allow the patient to continue oestrogen therapy (essential to maintain secondary female sexual characteristics).
Similarly, for women with previous VTE for whom tamoxifen is considered the optimal adjuvant hormonal therapy, extended anticoagulation should be considered (Watson et al, 2015) .
Recurrent VTE in women
The risk of recurrent VTE following initial treatment is determined by site of initial VTE, the presence/absence of provoking factors at initial presentation, with gender and biomarkers also reported to predict recurrence. Distal DVT has low risk of VTE recurrence and, due to low risk of embolization, guidance now recommends against treating these events in the absence of risk factors for extension and/ or confirmed lack of extension on serial imaging (Bates et al, 2012; NICE, 2012) . VTE provoked by major surgery has the lowest rate of unprovoked recurrence at <1% at 1 year with transient non-surgical risk factors associated with a risk of 3% per year. Unprovoked and cancer-associated VTE confer a higher risk of VTE recurrence NICE, 2012) .
Male gender was first reported as conferring a greater risk of recurrence following completion of anticoagulation for unprovoked VTE in 2004, with a cumulative recurrence rate at 5 years of 30Á7% compared to 8Á5% in women (Kyrle et al, 2004) . They reported no difference in rate of recurrence in women following VTE associated with hormone use compared to non-hormone users. A subsequent patient level metaanalysis of seven studies investigating the role of D-dimer in predicting recurrence following treatment for VTE confirmed a lower rate of VTE recurrence in women (HR for men 2Á2, 95% CI 1Á7-2Á8) and reported a lower rate of recurrence in women with VTE associated with oral hormone use (HR 0Á5, 95% CI 0Á3-0Á8) compared to women without (Douketis et al, 2011) . Kiconco et al (2017) utilised the UK Clinical Practice Research Datalink to investigate the role of hormone therapy further and also reported a lower risk of VTE recurrence in women with hormone use prior to VTE. Of note, this study included both progestin-only and combined oral contraceptives and all HRT (including transdermal) combinations. Given the lack of confirmed association between progestin preparations and VTE, and lower risk of VTE with transdermal HRT preparations, the inclusion of these groups may limit the applicability of this finding. Conversely, the REVERSE cohort study reported that, whilst recurrence rate following VTE associated with oral oestrogen was low (annual risk 3Á8%, 95% CI 0Á8-6Á8), it was not significantly different to female non-users following a first unprovoked event (HR 1Á2, 95% CI 0Á5-3Á1) (Le Gal et al, 2010 ).
An ISTH position statement in 2016 classified oestrogen, pregnancy or puerperium as a minor transient risk factor when present in the 2 months before VTE diagnosis, and recommends anticoagulation is withdrawn at 3 months (Kearon et al, 2016) . Similarly, the ACCP considers hormone-associated VTE to be provoked and recommends treatment for 3 months over treatment of a longer duration (Grade 1B) . The NICE clinical guideline, CG144, qualifies provoked VTE as those associated with pregnancy or puerperium within the last 3 months or hormonal therapy, with the recommended duration of treatment of 3 months (NICE, 2012) . In contrast, the derivation and validation studies for HERDOO2 (Rodger et al, 2008 (Rodger et al, , 2017 suggest that the recurrence risk in users of exogenous oestrogen is modulated by additional patient factors similar to unprovoked VTE. ACCP and NICE guidelines recommend patients with unprovoked VTE are considered for an extended duration of anticoagulation NICE, 2012) .
There are now three validated risk stratification tools to individualise duration of anticoagulation following an unprovoked VTE (Rodger et al, 2008; Eichinger et al, 2010; Tosetto et al, 2012) ; these are summarised in Table I . Of note, gender features in all tools with HERDOO2 a specific tool for use in women to identify those at low risk of recurrence who can safely discontinue anticoagulation at 3 months (Rodger et al, 2017) , and is the only prospectively validated tool. Current ISTH recommendations suggest that it is appropriate to stop anticoagulants in subgroups with a point estimate of recurrent VTE below 5% at 1 year, provided the upper limit of the 95% CI is less than 8% (Kearon et al, 2010) . The validation cohort found a higher than expected recurrence rate (5Á7%, 95% CI 2Á6-10Á9%) in low risk women aged >50 years, suggesting further validation is required in this (Tosetto et al, 2012 (Tosetto et al, , 2017 Validation (N = 827) (Tosetto et al, 2017) Derivation (N = 646) (Rodger et al, 2008) Validation (N = 2747) (Rodger et al, 2017) Derivation (N = 929) (Eichinger et al, 2010 (Eichinger et al, , 2014 Validation (N = 904) (Marcucci et al, 2015) Study design (Tosetto et al, 2012 (Tosetto et al, , 2017 Validation (N = 827) (Tosetto et al, 2017) Derivation (N = 646) (Rodger et al, 2008) Validation (N = 2747) (Rodger et al, 2017) Derivation (N = 929) (Eichinger et al, 2010 (Eichinger et al, , 2014 Validation (N = 904) (Marcucci et al, 2015) Exclusion criteria (Tosetto et al, 2012 (Tosetto et al, , 2017 Validation (N = 827) (Tosetto et al, 2017) Derivation (N = 646) (Rodger et al, 2008) Validation (N = 2747) (Rodger et al, 2017) Derivation (N = 929) (Eichinger et al, 2010 (Eichinger et al, , 2014 Validation (N = 904) (Marcucci et al, 2015) Limitations Requires the use of an online calculator BMI, body mass index; CHC, combined hormonal contraception; CI, confidence interval; DOACs, direct oral anticoagulants; DVT, deep vein thrombosis; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VKA, vitamin K antagonist; VTE, venous thromboembolism. *http://www.meduniwien.ac.at/user/georg.heinze/dvpm/. †(DASH) For abnormal D-dimers reported in validation study the following parameters were used D-dimer qualitative -'abnormal' or >500 ng/ml in a quantitative test. Tosetto and colleagues median of 30 days after anticoagulation therapy stopped. ‡(DASH) Index VTE occurring in the absence of surgery, trauma, active cancer, immobility or pregnancy or puerperium. §(HERDOO2) Defined as absence of leg fracture or lower extremity cast, immobilisation for greater than 3 days, or surgery using a general anaesthetic in the 3 months before the index event and without a diagnosis of malignant disease in last 5 months. ¶(HERDOO2) Defined as known deficiency of protein S, protein C or antithrombin, persistently positive anticardiolipin antibodies, known persistently positive lupus anticoagulant or who had two or more known thrombophilia defects. **(Vienna) VTE provoked by surgery, trauma, pregnancy, female hormone intake, natural inhibitor deficiency, lupus anticoagulant or cancer were excluded. group. VTE associated with exogenous oestrogen was associated with a higher risk of VTE recurrence (6Á8%, 95% CI 3Á1-12Á8%) in low risk women aged >50 years (but not in women aged <50 years).
Adverse effects of anticoagulation in women

Bleeding
A web-based questionnaire collecting bleeding histories from healthy individuals (n = 500) demonstrated women reported more bleeding symptoms compared with men; however, when sex-specific bleeding questions were excluded, the frequency of bleeding was no different (Mauer et al, 2011) . Female gender was included as a risk factor in an early bleeding prediction score derived empirically from bleeding risk factors reported in the literature and validated in a single cohort of patients with VTE managed with VKAs (Kuijer et al, 1999) . Female gender was not subsequently found to be significantly associated with bleeding risk in 19 274 patients on anticoagulation for VTE (Ru ız-Gim enez et al, 2008) .
A systematic review and meta-analysis of the pivotal phase III studies of DOACs for treatment and secondary prevention of VTE demonstrated less major bleeding/clinically relevant non-major bleeding in males (RR 0Á79, 95% CI 0Á66-0Á97). Of note, they also found a significant reduction in bleeding in men within the placebo arms of included trials (RR 0Á48, 95% CI 0Á24-0Á95), suggesting pre-existing sex-specific differences (Alotaibi et al, 2013) .
Abnormal uterine bleeding. Abnormal uterine bleeding, encompassing both abnormal bleeding during menstruation and intermenstrual bleeding, affects at least 10-30% of women of child-bearing potential and is known to negatively impact on patient-reported quality of life (Liu et al, 2007) . HMB is a more specific term referring to excess bleeding at menstruation, defined as >80 ml/cycle or clinically excessive menstrual loss that interferes with a woman's physical, emotional, social or material quality of life (Fraser et al, 2011) . HMB associated with anticoagulation is well documented, with the prevalence in women on warfarin reported as 22-65% (Boonyawat et al, 2017a) . Withdrawal of CHCs around the time that anticoagulation is initiated in VTE may well contribute to the high incidence of HMB in pre-menopausal women, as previously described (Beyer-Westendorf et al, 2016b) .
Post hoc analyses of the pivotal phase III trials of DOACs for VTE treatment are summarised in Table II and reports  from real world experience in Table III . Cross study comparison is limited due to variation in definition of the endpoint of AUB. Of note, the highest rates of AUB were reported in the study administering a questionnaire to specifically evaluate this outcome (De Crem et al, 2015) . It is likely that AUB/HMB rates reported in other studies underestimate the true incidence as women may accept HMB as 'normal' whilst on anticoagulation and only report if directly questioned regarding this adverse event. Of note, AUB is also reported in older women; the RIETE registry report an incidence of major uterine bleeding of 0Á17% (95% CI 0Á13-0Á21) at a mean age of 56 (AE17) years, with 60% of major uterine bleeds occurring in women >50 years old. Patients with major bleeds were more likely to have cancer, anaemia and/ or a raised platelet count at the time of index VTE presentation (Moustafa et al, 2017) .
Given that rivaroxaban was the first factor Xa inhibitor licenced for the treatment of acute VTE it is unsurprising that it features in the majority of real-world reports of AUB. Further comparative work is underway with the RAMBLE study in the US; this study will compare HMB in women on rivaroxaban or apixaban with a primary outcome of pictorial blood assessment chart scores greater than 100 (Clinicaltrials.gov NCT02829957).
Management of HMB.
Depending on the time elapsed from VTE diagnosis, temporary withdrawal or a dose reduction of anticoagulation during menstruation may be sufficient (Ferreira et al, 2016) . However strict adherence to treatment should be emphasised during the first 3 months of treatment, due to the increased risk of VTE recurrence in this initial treatment phase. Boonyawat et al (2017b) described a dose dependence of HMB with rivaroxaban following a prospective analysis of women enrolled in the EINSTEIN CHOICE study. Data from 353 women showed that menstrual flow length increased in 12Á6-18Á4% of women given rivaroxaban 20 mg and only in 6Á0-12Á8% of women given rivaroxaban 10 mg (Boonyawat et al, 2017b) . Switching to an alternative agent has also been reported as effective by Myers and Webster (2017) , with some women reporting resolution of symptoms upon switching from rivaroxaban to apixaban. Lower rates of AUB have been reported with warfarin compared with rivaroxaban and edoxaban, suggesting this as an alternate treatment option for women needing to continue anticoagulation and unable to tolerate a DOAC due to HMB (Martinelli et al, 2016; Scheres et al, 2018) . A small single centre prospective study of women treated with warfarin or rivaroxaban reported an association between HMB and recurrent VTE, leading to postulation that interruption of anticoagulation may predispose to this increased risk (Bryk et al, 2016) . Further confirmatory studies are required but physicians initiating women on anticoagulants should be aware of this potential adverse event and counsel women to seek medical attention in the event of HMB to prevent temporary or permanent discontinuation of anticoagulation.
Hormonal therapy. The NICE guideline NG44 recommends a LNG IUD as the first-line treatment for HMB (assuming no identified pathology, fibroids less than 3 cm in diameter, which are not causing distortion of the uterine cavity or suspected or diagnosed adenomyosis). A LNG IUD significantly reduces menstrual flow compared with CHCs, for women on and off anticoagulation therapy, and is considered safe for women with a history of VTE (Lidegaard et al, 2012; FSRH, 2016; Rivara & James, 2018) . Where LNG IUD is declined or unsuitable, CHCs or cyclical progestins are recommended (NICE, 2018b).
Non-hormonal therapy. Tranexamic acid, an antifibrinolytic agent, is an effective treatment for HMB. Whilst current/previous VTE is listed as a contraindication in the product license, an expert panel review favoured its use as a method of managing HMB in women on anticoagulation for acute VTE (Klok et al, 2017) . There is a lack of safety and efficacy data in patients with VTE; however large prospective RCTs of tranexamic acid in other settings, including acute traumatic bleeding, postpartum haemorrhage and intracranial bleeding, did not demonstrate any increase in VTE events, suggesting this is not a significant adverse effect (WilliamsJohnson et al, 2010; Shakur et al, 2017; Sprigg et al, 2018) .
Alopecia and anticoagulation
Whilst not limited to women, alopecia is a frequently reported side effect by patients attending anticoagulation clinics. Women are more likely to report this side effect due to more frequent grooming and as men may attribute hair loss to the normal aging process. Traditional anticoagulants are known to cause hair pathology, with alopecia being most reported (Tudhope et al, 1958) . Experience with DOACs to date would also suggest that they too, may cause these adverse effects (Vigibase; http://www.vigiaccess.org//). It is suggested that the mechanism of hair loss associated with anticoagulants is telogen effluvium (the premature shifting of hair follicles from the growing phase, anagen, to the shedding phase) (Watras et al, 2016) . Telogen effluvium presents typically 2-4 months after a trigger. Cases of hair loss associated with warfarin range from 2 months up to 13 years. Dermatologists reviewing three cases of alopecia associated with enoxaparin also diagnosed telogen effluvium although other processes could not be ruled out (Wang & Po, 2006) . The Dresden NOAC registry reported an incidence of alopecia of 4Á4 per 100 patient years in spontaneous selfreports from women prescribed rivaroxaban (9/730) and dabigatran (3/208) following a treatment duration of 22-260 days (Gelbricht et al, 2012) . Whilst this may be considered a non-significant side effect to physicians, it may lead to patient to non-adherence (Chr etien et al, 2015) .
Conclusions
Venous thrombosis is a global health issue and poses unique challenges in women. On one hand, pregnancy and hormonal therapies increase the risk of VTE. On the other, women have a lower risk of recurrence than men following unprovoked VTE. Our understanding of the factors associated with recurrence of VTE in women is increasing and DOACs provide a convenient long-term anticoagulation option. The higher frequency of AUB is a significant clinical issue but reduced dose regimens for secondary VTE prevention might be part of the solution. For special patient groups, in whom evidence is limited, such as pregnant or breastfeeding women, a collaborative approach is needed to gather and analyse meaningful data to evaluate safety following exposure to the DOACs. We await further research in the areas discussed within this review with anticipation.
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